Total Funding
49
56
Total FundingVenture - Series Unknown raised
Growth Score
-21 pts
Heat Score
-9 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
28791
Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis.
Cynthia Bamdad: CEO
About the Company
Minerva Biotechnologies develops cancer immunotherapies and cancer drugs to target 80% of solid tumors and to prevent cancer metastasis. Its stem cell technology could transform the field of regenerative medicine. It discovered that cancer cells are healthy cells that are being reprogrammed back to a stem cell state. It is also the first company to
generate human naïve state pluripotent stem cells using a single, naturally occurring human stem cell growth factor. These earlier stem cells have a clean slate and are more easily directed to develop into functional mature cells, which could be used for transplant.
It was founded in 1999 and is headquartered in Waltham, Massachusetts.
Women Founded
Women Led
